Status:
TERMINATED
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
Lead Sponsor:
YM BioSciences
Conditions:
Breast Cancer
Metastases
Eligibility:
FEMALE
16+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but...
Detailed Description
Endpoints of the trial are as follows: primary: overall survival; secondary: response rate, progression free survival, toxicity, neurocognitive function.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histological proof of breast cancer
- Documented evidence of metastatic and/or recurrent breast cancer
- Presence of at least one bi-dimensional or uni-dimensional lesion
- ECOG status 0, 1 or 2
- Quality of life
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT00099281
Start Date
May 1 2004
End Date
June 1 2006
Last Update
February 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PharmOlam
London, United Kingdom